This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
Source：MarketWatch
友情提醒：請廣大讀者理性看待市場資訊，切實提高風險意識。站內所有內容僅系市場資訊或相關方觀點，不構成任何形式投資建議。